A Global Crisis
The discovery of antibiotics was heralded as one of the greatest medical discoveries in modern history and the drugs quickly became the cornerstone of modern medicine. Antibiotics made life saving surgery, chemotherapy, organ transplants and care of premature infants possible.
Yet after 80 years of significant overuse in human medicine and agriculture, antibiotics are losing their effectiveness. It is estimated that up to 50% of all prescribed antibiotics are either not needed—such as antibiotics given to treat viral infections—or are not properly “matched” to the bacteria they’ve been prescribed to treat, and therefore are not as effective as they could be.
Antimicrobial Resistance has led to a sharp increase in drug-resistant infections around the world. As a result, antibiotic resistance is now one of the greatest public health threats of our time, with substantial impacts on people, health care systems and economies worldwide. Without urgent action, it is estimated that by 2050, 10 million people a year will die from drug-resistant infections and $100 trillion in global economic productivity will have been lost over that time period.
- Over 2,000,000 Antimicrobial-Resistant Infections
- At Least 23,000 Deaths Every Year
- At least 30% of antibiotics prescribed in the US doctor’s offices and Emergency Departments are unnecessary
- Antimicrobial Resistance Disproportionately Affects Our Children and Elderly
xymbio offers a critical link in the physician’s response to an infected patient and one that is sometimes overlooked in stewardship discussions and models. Rapid diagnostics for distinguishing between viral and bacterial infections greatly facilitate the decision of whether or not to prescribe which antibiotics. xymbio’s proprietary solutions bring much-needed products and services to aid physicians in the arenas of bedside, clinic and field diagnosis by rapidly matching disease agents with appropriate therapies.